258 related articles for article (PubMed ID: 35337068)
1. The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights.
Toussirot E
Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337068
[TBL] [Abstract][Full Text] [Related]
2. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J; Kiltz U; Baraliakos X
Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
[TBL] [Abstract][Full Text] [Related]
3. Pain in axial spondyloarthritis: role of the JAK/STAT pathway.
Selmi C; Chimenti MS; Novelli L; Parikh BK; Morello F; de Vlam K; Ciccia F
Front Immunol; 2024; 15():1341981. PubMed ID: 38464510
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Janus kinase inhibitors in axial spondyloarthritis.
Daoud A; Magrey MN
Indian J Dermatol Venereol Leprol; 2023 Jun; ():1-9. PubMed ID: 37436016
[TBL] [Abstract][Full Text] [Related]
5. JAK Inhibitors for the Treatment of Axial Spondyloarthritis.
Klavdianou K; Papagoras C; Baraliakos X
Mediterr J Rheumatol; 2023 Jun; 34(2):129-138. PubMed ID: 37654636
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
[TBL] [Abstract][Full Text] [Related]
7. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Hammitzsch A; Lorenz G; Moog P
Front Immunol; 2020; 11():591176. PubMed ID: 33193430
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT Signaling and Beyond in the Pathogenesis of Spondyloarthritis and Their Clinical Significance.
Raychaudhuri SP; Shah RJ; Banerjee S; Raychaudhuri SK
Curr Rheumatol Rep; 2024 Jun; 26(6):204-213. PubMed ID: 38492148
[TBL] [Abstract][Full Text] [Related]
9. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
Akkoc N; Khan MA
Curr Rheumatol Rep; 2021 Apr; 23(6):34. PubMed ID: 33909185
[TBL] [Abstract][Full Text] [Related]
10. Emerging treatment options for spondyloarthritis.
Torgutalp M; Poddubnyy D
Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):472-484. PubMed ID: 31171316
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
12. Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents.
Tahir H; Byravan S; Fardanesh A; Moorthy A
J Exp Pharmacol; 2021; 13():627-635. PubMed ID: 34257507
[TBL] [Abstract][Full Text] [Related]
13. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
[TBL] [Abstract][Full Text] [Related]
14. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Veale DJ; McGonagle D; McInnes IB; Krueger JG; Ritchlin CT; Elewaut D; Kanik KS; Hendrikx T; Berstein G; Hodge J; Telliez JB
Rheumatology (Oxford); 2019 Feb; 58(2):197-205. PubMed ID: 29618084
[TBL] [Abstract][Full Text] [Related]
15. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
[TBL] [Abstract][Full Text] [Related]
16. Role of Janus Kinase Inhibitors in Therapy of Psoriasis.
Słuczanowska-Głąbowska S; Ziegler-Krawczyk A; Szumilas K; Pawlik A
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640327
[TBL] [Abstract][Full Text] [Related]
17. Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.
Paroli M; Caccavale R; Paroli MP; Spadea L; Accapezzato D
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674537
[TBL] [Abstract][Full Text] [Related]
18. Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
O'Brien A; Hanlon MM; Marzaioli V; Wade SC; Flynn K; Fearon U; Veale DJ
Front Immunol; 2021; 12():672461. PubMed ID: 34248953
[TBL] [Abstract][Full Text] [Related]
19. Selective JAK-Inhibitors in Spondyloarthritis.
Vassilakis KD; Magiouf K; Siebert S; Fragoulis GE
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):27-36. PubMed ID: 38756935
[TBL] [Abstract][Full Text] [Related]
20. Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.
Mease P
Curr Rheumatol Rep; 2019 Jun; 21(7):35. PubMed ID: 31172311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
